A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 94, Issue 9, 1999, Pages 2496-2500

  Hwang, Shinn Jang ^a   Lee, Shou Dong ^a   Chan, Cho Yu ^a   Lu, Rei Hwa ^a   Chang, Full Young ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CONSENSUS INTERFERON;

ADULT; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CHINA; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED;

EID: 0033198578     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.01382.x     Document Type: Article

References (28)

1. Seeff LB. Nature history of hepatitis C. Hepatology 1997;26: 21S-8S.
2. Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991;14:969-74.
3. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
4. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
5. Tong MJ, El-Farra NS, Reikes AR, et al. Clinical outcome after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-6.
6. Davis GL, Baiart LA, Schiff ER, et al, Hepatitis Interventional Therapy Group. Treatment of chronic hepatitis C with recombinant Interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
7. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C, a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-10.
8. Hwang SJ, Chan CY, Lu RH, et al. Randomized controlled trial of recombinant interferon-a 2b in the treatment of Chinese patients with chronic hepatitis C. J Interferon Cytokine Res 1995;15:611-6.
9. Carithers RL, Emerson SS. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trail. Hepatology 1997;26:83S-8S.
10. Lee WM. Therapy of hepatitis C: Interferon alfa-2a trail. Hepatology 1997;26:89S-95S.
11. Farrell GC. Therapy of hepatitis C: Interferon alfa-nl trials. Hepatology 1997;26:96S-100S.
12. Glaspy JA, Souza L, Scales S, et al. Treatment of hairy cell leukemia with granulocyte colony stimulating factor and recombinant consensus interferon or recombinant interferon alfa-2b. J Immunother 1992;11;198-208.
13. Ozes ON, Reiter Z, Klein S, et al. A comparison of interferon con 1 with natural recombinant interferon-alpha: Antiviral, antiproliferative, and natural killer inducing activities. J Interferon Res 1992;12:55-9.
14. Klein SB, Blatt LM, Taylor MW. Consensus interferon induces peak mRNA accumulation at lower concentration than interferon-a 2a. J Interferon Res 1993;13:341-7.
15. Blatt LM, Davis JM, Klein SB, et al. The biological activity and molecular characterization of a novel synthetic interferon alpha species, consensus interferon. J Interferon Cytokine Res 1996:16:489-99.
16. Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trail. Hepatology 1997;26:747-54.
17. Heathcote EJL, Keeffe EB, Lee SS, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998:27:1136-43.
18. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993:341:1501-4.
19. Chan CY, Lee SD, Hwang SJ, et al. Quantitative branched DNA assay and genotyping for hepatitis C virus RNA in Chinese patients with acute and chronic hepatitis C. J Infect Disease 1995;171:443-6.
20. Hwang SJ, Lee SD, Lee-Wu YH, et al. A randomized controlled clinical trail of recombinant interferon a-2b in the treatment of acute post-transfusion hepatitis C-A preliminary report. J Gastroenterol Hepatol 1993;8:S92-8.
21. Okamoto H, Okada S, Sugiyama Y, et al. The 5'-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990:60:167-77.
22. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
23. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994:19:1321-4.
24. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: Multicenter randomized controlled trial. Hepatology 1995;21:291-7.
25. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology 1995;22:700-6.
26. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996:24:778-89.
27. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996:111:1307-12.
28. Yao GB, Fu XX, Xu DZ, et al. A randomized, comparative, multicenter study of consensus interferon (CIFN) with interferon alfa-2a in patients with chronic hepatitis C virus infection. Hepatology 1997;26:422A.